Contents
Ireland has pursued a cautious and tightly controlled approach to medical cannabis. The launch of the Medical Cannabis Access Programme (MCAP) in 2019 marked a significant development, offering patients with specific health conditions a regulated pathway to treatment. However, access remains highly limited, with complex regulatory requirements and a narrow scope of eligibility.
The Medical Cannabis Access Programme (MCAP)
The Medical Cannabis Access Programme was established to provide legal access to cannabis-based treatments for patients with severe, treatment-resistant conditions. Eligibility is currently confined to three indications: spasticity associated with multiple sclerosis, nausea arising from chemotherapy, and intractable neuropathic pain. Prescriptions must be issued by specialist physicians with direct expertise in these conditions.
Although MCAP provides a formalised structure, uptake has been modest. The limited range of approved conditions, combined with administrative hurdles, continues to restrict the number of patients benefitting from the programme.
Ministerial Licence Pathway
Prior to the introduction of MCAP, patients could only obtain cannabis through ministerial licences granted by the Minister of Health. This pathway remains in operation but is generally considered burdensome, with lengthy and bureaucratic application processes. For patients outside MCAP’s strict eligibility criteria, it often remains the only option, despite the significant administrative challenges involved.
Reimbursement and Costs
The cost of treatment is a key factor influencing access. Patients enrolled in MCAP may qualify for reimbursement if they hold a health card, part of Ireland’s means-tested public healthcare framework. Those accessing cannabis via ministerial licence must pay the full cost of treatment directly. This distinction creates inequity between patients within the same therapeutic landscape, depending on their route of access.
Product Availability
Product choice in Ireland remains extremely limited. Under MCAP, a small number of extract-based cannabis products are approved for use. Patients on ministerial licences are restricted to Bedrocan products, which must be converted into extracts by a magistral pharmacy in the Netherlands before distribution. Furthermore, many products are imported on a per-prescription basis, adding delays and increasing costs for patients.
Challenges and Outlook
Ireland’s framework demonstrates progress compared with a decade ago but continues to face structural barriers. Narrow eligibility criteria, high costs outside of the public reimbursement system, and reliance on imports restrict patient access and place pressure on prescribers. Unless eligibility is broadened and the range of approved products expanded, patient numbers are likely to remain small. However, ongoing policy review may open opportunities for future reform, particularly as evidence from other European markets continues to build.
Frequently Asked Questions
Yes. Medical cannabis is legal in Ireland under two frameworks: the Medical Cannabis Access Programme (MCAP) and the ministerial licence pathway. Both provide regulated but highly restricted access.
Currently, only three conditions are eligible: spasticity from multiple sclerosis, chemotherapy-induced nausea, and treatment-resistant neuropathic pain.
Patients not eligible for MCAP may apply for a ministerial licence through the Minister of Health. The process is lengthy and bureaucratic, requiring specialist medical support.
Patients with a health card may qualify for reimbursement under MCAP. Those using the ministerial licence pathway must pay the full cost of treatment.
MCAP provides access to a small list of extract-based products. Under ministerial licence, only Bedrocan products are permitted, which are processed into extracts in the Netherlands before reaching patients.
